Literature DB >> 1686790

Involvement of oxygen-derived free radicals in the pathogenesis of chronic inflammatory bowel disease.

O H Nielsen1, I Ahnfelt-Rønne.   

Abstract

Ulcerative colitis and Crohn's disease are chronic inflammatory bowel diseases. The most widely prescribed drug for treatment of these diseases, sulfasalazine, has been shown to inhibit the activity of free radicals, as the active moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. This effect of 5-aminosalicylic acid may be of clinical relevance, as a recent study has shown that 5-aminosalicylic acid reacts with oxygen-derived free radicals formed in the intestine in this disease. Reaction with free radicals does not, however, occur in patients with rheumatoid arthritis treated with the same agent. Furthermore, a significant correlation exists between the activity in the intestine of free radicals, as measured by the rate of lipid peroxidation, and the disease activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686790     DOI: 10.1007/bf01645145

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  22 in total

Review 1.  Rationales for drug development in inflammation: eicosanoids and oxygen-derived free radicals.

Authors:  I Ahnfelt-Rønne
Journal:  Dan Med Bull       Date:  1991-08

2.  In vitro studies on the significance of arachidonate metabolism and other oxidative processes in the inflammatory response of human neutrophils and macrophages. With special reference to chronic inflammatory bowel disease.

Authors:  O H Nielsen
Journal:  Scand J Gastroenterol Suppl       Date:  1988

Review 3.  Sulfasalazine and related new drugs.

Authors:  M A Peppercorn
Journal:  J Clin Pharmacol       Date:  1987-04       Impact factor: 3.126

4.  Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas.

Authors:  W S Selby; M K Bennett; D P Jewell
Journal:  Digestion       Date:  1984       Impact factor: 3.216

5.  Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease.

Authors:  O H Nielsen
Journal:  Scand J Gastroenterol       Date:  1982-04       Impact factor: 2.423

6.  The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger.

Authors:  I Ahnfelt-Rønne; O H Nielsen
Journal:  Agents Actions       Date:  1987-06

7.  Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.

Authors:  Y Miyachi; A Yoshioka; S Imamura; Y Niwa
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

8.  Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.

Authors:  O H Nielsen; K Bukhave; J Elmgreen; I Ahnfelt-Rønne
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

9.  Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation.

Authors:  B Samuelsson
Journal:  Science       Date:  1983-05-06       Impact factor: 47.728

10.  Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid.

Authors:  I Ahnfelt-Rønne; O H Nielsen; A Christensen; E Langholz; V Binder; P Riis
Journal:  Gastroenterology       Date:  1990-05       Impact factor: 22.682

View more
  4 in total

Review 1.  Concepts of oxidative stress and antioxidant defense in Crohn's disease.

Authors:  Mohammed A Alzoghaibi
Journal:  World J Gastroenterol       Date:  2013-10-21       Impact factor: 5.742

2.  Influence of disease site and activity on peripheral neutrophil function in inflammatory bowel disease.

Authors:  A D'Odorico; R D'Inca; C Mestriner; V Di Leo; A Ferronato; G C Sturniolo
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

3.  Targeting oxidative stress attenuates trinitrobenzene sulphonic acid induced inflammatory bowel disease like symptoms in rats: role of quercetin.

Authors:  Dilip Dodda; Ruchi Chhajed; Jitendriya Mishra; Monalisa Padhy
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200

4.  Benefits of Zataria multiflora Boiss in Experimental Model of Mouse Inflammatory Bowel Disease.

Authors:  Leila Ashtaral Nakhai; Azadeh Mohammadirad; Narges Yasa; Bagher Minaie; Shekoufeh Nikfar; Ghazal Ghazanfari; Mohammad Jafar Zamani; Gholamreza Dehghan; Hamidreza Jamshidi; Vahid Shetab Boushehri; Reza Khorasani; Mohammad Abdollahi
Journal:  Evid Based Complement Alternat Med       Date:  2006-09-14       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.